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Abstract: Only some individuals with obesity develop liver fibrosis due to non-alcoholic fatty
liver disease (NAFLD-fibrosis). We determined whether detailed assessment of lifestyle factors in
addition to physical, biochemical and genetic factors helps in identification of these patients. A
total of 100 patients with obesity (mean BMI 40.0 ± 0.6 kg/m2) referred for bariatric surgery at the
Helsinki University Hospital underwent a liver biopsy to evaluate liver histology. Physical activity
was determined by accelerometer recordings and by the Modifiable Activity Questionnaire, diet
by the FINRISK Food Frequency Questionnaire, and other lifestyle factors, such as sleep patterns
and smoking, by face-to-face interviews. Physical and biochemical parameters and genetic risk
score (GRS based on variants in PNPLA3, TM6SF2, MBOAT7 and HSD17B13) were measured. Of
all participants 49% had NAFLD-fibrosis. Independent predictors of NAFLD-fibrosis were low
moderate-to-vigorous physical activity, high red meat intake, low carbohydrate intake, smoking,
HbA1c, triglycerides and GRS. A model including these factors (areas under the receiver operating
characteristics curve (AUROC) 0.90 (95% CI 0.84–0.96)) identified NAFLD-fibrosis significantly
more accurately than a model including all but lifestyle factors (AUROC 0.82 (95% CI 0.73–0.91)) or
models including lifestyle, physical and biochemical, or genetic factors alone. Assessment of lifestyle
parameters in addition to physical, biochemical and genetic factors helps to identify obese patients
with NAFLD-fibrosis.
Keywords: physical activity; diet; stress; glucose; insulin
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from simple steatosis
(NAFL) to non-alcoholic steatohepatitis (NASH) and various stages (F1–F4) of fibrosis [1].
Fibrosis is the best predictor of mortality in NAFLD [2,3]. The prevalence of liver fibrosis
due to NAFLD (NAFLD-fibrosis) averages 40% (≥F1, range 13–97%) in patients with
morbid obesity [4]. The reason for this interindividual variation is poorly understood, as
data on predictors of histologically determined NAFLD-fibrosis are sparse.
Previous studies have mainly explored associations between physical factors, such as
measures of body weight and composition, and biochemical parameters including features
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of the metabolic syndrome, and NAFLD-fibrosis [5–8]. The possibility that assessment
of several lifestyle-related factors such as diet, physical activity, fatigue and stress and
sleep patterns in addition to physical and biochemical features and common powerful
genetic variants (vide infra) help in predicting biopsy-proven NAFLD-fibrosis has not been
explored. There are some data on single lifestyle factors and their relationship to NAFLD-
fibrosis. Adherence to a Mediterranean diet was significantly less frequent in those with
NAFLD-fibrosis compared to those without in a cross-sectional study of 82 patients with
obesity [9], and high daily fructose consumption was found to be significantly associated
with liver fibrosis in another cross-sectional study [10]. Self-reported physical activity (PA)
has been found to associate inversely with fibrosis stage in NAFLD [11], but there are no
data relating objectively quantified PA to NAFLD-fibrosis. Regarding other lifestyle factors,
daytime sleepiness was positively correlated with the degree of fibrosis in a cross-sectional
study of 46 patients with biopsy-proven NAFLD and 22 healthy controls [12]. Advanced
NAFLD-fibrosis may also be more common in smokers than in non-smokers [13].
Common genetic polymorphisms in patatin-like phospholipase domain-containing 3
(PNPLA3) at rs738409, transmembrane 6 superfamily member 2 (TM6SF2) at rs58542926,
membrane-bound O-acyltransferase domain-containing 7 (MBOAT7) at rs641738 and 17-
beta-hydroxysteroid dehydrogenase (HSD17B13) at rs72613567 have been shown to ro-
bustly influence the risk of NAFLD-fibrosis [14]. Polygenic risk scores have emerged as a
powerful tool in studying the compound effect of multiple genetic variants on phenotype
in multifactorial diseases [15]. Recently, Gellert-Kristensen et al. showed that a genetic
risk score (GRS) incorporating the NAFLD risk-modifying alleles in PNPLA3, TM6SF2
and HSD17B13 was significantly associated with cirrhosis [16]. Whether GRS helps in
diagnosing NAFLD-fibrosis in patients with obesity, whose physical and biochemical and
lifestyle parameters have been assessed, is unknown.
Thus, in the present study, we were interested in determining whether simultaneous
assessment of multiple lifestyle factors including diet, objectively measured physical
activity, fatigue and stress, sleep patterns, employment status and smoking, in addition
to physical, biochemical and genetic factors, helps in identification of NAFLD-fibrosis.
This would seem valuable, as assessment of lifestyle habits is inexpensive and important
for educational and therapeutic purposes in the clinic. For this, we comprehensively
characterized these factors as schematically depicted in Figure 1 in 100 obese patients who
underwent a liver biopsy.
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Figure 1. An overview of lifestyle and genetic factors investigated in the study. Abbreviations:
HSD17B1, 17-β hydroxysteroid dehydrogenase; MBOAT7, membrane bound O-acyltransferase
domain containing 7; NAFLD, non-alcoholic fatty liver disease; PNPLA3, patatin-like phospholipase
domain-containing protein 3; TM6SF2, transmembrane 6 superfamily member 2.
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2. Materials and Methods
2.1. Participants
We prospectively recruited 100 consecutive participants amongst those referred for
bariatric surgery at the Helsinki University Hospital (Helsinki, Finland). The participants
were eligible if they met the following inclusion criteria: (a) age 18 to 75 years; (b) no known
acute or chronic disease except for obesity, type 2 diabetes or hypertension on the basis
of medical history, physical examination and standard laboratory tests (complete blood
count, serum creatinine, C-reactive protein, thyroid stimulating hormone and electrolyte
concentrations); (c) alcohol consumption less than 20 g per day for women and less than
30 g per day for men; (d) no evidence of liver conditions other than NAFLD such as
autoimmune, drug-induced or viral liver disease; (e) no history of use of toxins or drugs
associated with liver steatosis; (f) not pregnant or lactating.
The study protocol was approved by the ethics committee of the Hospital District of
Helsinki and Uusimaa (78/13/03/01/2015), and it was performed in accordance with the
Declaration of Helsinki. Each participant provided their written informed consent after
being explained the nature and potential risks of the study.
2.2. Study Design
Prior to bariatric surgery, the participants were invited to two separate visits to
the Clinical Research Unit for comprehensive characterization of lifestyle, physical and
biochemical, and genetic factors.
At the first visit, approximately two weeks prior to surgery, informed consent was
obtained, body height and weight were recorded, and a tri-axial accelerometer was pro-
vided to be worn for the following seven days, as detailed below. At the second visit,
approximately one week prior to surgery, blood samples were taken for laboratory tests
and genotyping, as detailed below. Physical measurements and face-to-face interviews as-
sessing medical history, duration of obesity, smoking habits, diet (FINRISK Food Frequency
Questionnaire), PA (Modifiable Activity Questionnaire), fatigue (Fatigue Impact Scale) and




(i) Accelerometer recordings. At the first clinical visit, the participants were pro-
vided with a tri-axial accelerometer (ActiGraph wGT3X-BT, Actigraph LLC, Pensacola,
FL, USA) to be worn on their right hip during waking hours except water-based activities
(e.g., showering) for the following seven days, while encouraged to maintain their normal
PA. The device measures body position (lying/sitting/standing) using an inclinometer.
Raw data were analyzed using Actilife 6.0 (Actigraph Software Department, Pensacola, FL,
USA). Cut points by Freedson Adult VM (2011) were used to convert raw accelerations
as counts per minute to PA intensities [17]. PA intensities were defined as: sedentary
behavior (<1.5 metabolic equivalents of task (METs)), light PA (1.5–3.0 METs), moderate PA
(3.1–6.0 METs) and vigorous PA (>6.0 METs). Only participants with recordings of ≥9 h
per day for ≥4 days were included to further analysis.
(ii) Modifiable Activity Questionnaire. In addition to accelerometer recordings, PA was
assessed using the Modifiable Activity Questionnaire (MAQ), translated into Finnish [18].
The questionnaire has been validated in several cohorts and shown to predict type 2
diabetes [18–20]. MAQ assesses in detail leisure and occupational PA as well as sedentary
behavior during the past 12 months. The average weekly energy expenditure (EE) of PA
and time spent in moderate-to-vigorous physical activity (MVPA) were calculated.
2.3.2. Diet
The FINRISK Food Frequency Questionnaire (FFQ) was used to characterize the diet
of the participants [21]. The FINRISK FFQ has been developed by the Finnish Institute for
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Health and Welfare to assess dietary patterns in Finns. It examines monthly, weekly and
daily intake of 56 food items, in addition to meal frequency, type and quality of selected
food items, and alcohol consumption. Food items were categorized as follows: grains
(e.g., biscuits, pizza, pasta, porridge), dairy products (e.g., yoghurt, cheese, ice cream),
potatoes and vegetables (e.g., steamed potato, french fries, salad), fruits and berries, fish
(e.g., salmon, Baltic herring), meat (e.g., red meat, poultry, cold cuts, eggs) and others
(e.g., chocolate, snacks, convenience foods) Food intake frequencies were quantified as:
never = 1, few portions in a month = 2, one portion a week = 3, two to four portions a
week = 4, five to six portions a week = 5, daily = 6. Nutritional composition and energy
percentages (E%) of macronutrients were determined by entering the FFQ data into the
National Food Composition Database of Finland [22]. Energy densities of macronutrients
were 4 kcal/g for carbohydrates, 4 kcal/g for proteins and 9 kcal/g for fats.
2.3.3. Sleep, Stress and Socioeconomic Factors
The Fatigue Impact Scale was used to assess fatigue symptoms in the participants [23].
The scale has been previously used for measuring fatigue amongst patients with NAFLD
and obesity [24,25]. The questionnaire assesses fatigue symptoms during the previ-
ous month with 40 items divided into three subdomains: cognitive (10 items), physical
(10 items) and psychosocial (20 items) [23].
The risk of sleep apnea was assessed using the Berlin Sleep Apnea Questionnaire,
which has been developed to identify individuals at a high risk for obstructive sleep apnea
in primary care [26]. The questionnaire consists of three domains and classifies patient as
having either a high or a low risk for sleep apnea.
Sleeping habits, smoking status, employment, duration of overweight, and medical
history, were assessed during the face-to-face interview.
2.4. Physical and Biochemical Factors, and Liver Histology
Activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl-
transferase (GGT) and concentrations of high-density lipoprotein (HDL) cholesterol and
low-density lipoprotein (LDL) cholesterol, triglycerides, glucose, glycosylated hemoglobin
A1c (HbA1c), insulin, albumin and platelet count were measured as described previously
in detail [27]. The homeostasis model assessment of insulin resistance (HOMA-IR) was
calculated using the formula: fasting glucose (mmol/L) × fasting insulin (mU/L)/22.5 [28].
Blood pressure as well as body weight, height, and hip and waist circumferences, and
waist-to-hip ratio (WHR), were measured as described in [29].
Wedge biopsies of the liver were obtained at the beginning of bariatric surgery. Liver
histology was analyzed by an experienced liver pathologist (J.A.) in a blinded fashion.
Fibrosis stage was reported as proposed by Brunt et al. [1] as: F0, absence of fibrosis; F1,
perisinusoidal or periportal fibrosis; F2, portal/periportal fibrosis; F3, bridging fibrosis;
and F4, cirrhosis. NAFLD-fibrosis was defined as F1-F4 and absence of fibrosis as F0.
2.5. Genetic Factors
Genotyping of PNPLA3 at rs738409, TM6SF2 at rs58542926, MBOAT7 at rs641738 and
HSD17B13 at rs72613567 was performed as previously described [30–32]. To investigate
the impact of all four single-nucleotide polymorphisms (SNPs) on NAFLD-fibrosis, a GRS
was calculated as suggested [16] by summing up the number of minor risk alleles (0–2) in
PNPLA3, TM6SF2 and MBOAT7, as well as major alleles (0–2) in HSD17B13. Thus, GRS
ranged from 0 to 8 [4].
2.6. Statistical Analyses
The D’Agostino-Pearson omnibus normality test was used to analyze the distribution
of continuous variables. Normally distributed data are shown as mean ± standard error
of mean (SEM) and non-normally distributed data as median followed by the 25th and
75th percentiles. The unpaired Student’s t test and Mann-Whitney U test were used to
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compare normally and non-normally distributed groups, respectively. Categorical data are
shown as proportions and compared using the Fisher’s exact test or the Chi-square test,
as appropriate.
For each variable, univariable logistic regression analysis was used to calculate odds
ratio (OR) and 95% confidence interval (CI) for NAFLD-fibrosis. Variables associated with
NAFLD-fibrosis at a significance level of ≤0.05 in univariable analysis were included in the
multivariable logistic regression using stepwise backward selection with 0.10 probability for
stepwise removal. If the variables measured essentially the same biological phenomenon
such as glucose/HbA1c, HOMA-IR/insulin, carbohydrate/protein/fat energy percent
[E%]), only the variable that was most significantly associated with NAFLD-fibrosis was
included. Five models were built by including in the analysis either lifestyle (1), physical
and biochemical (2), or genetic factors (3) alone, all but lifestyle factors (4), and finally, all
the factors (5). To measure abilities of the models to separate participants with and without
liver fibrosis, areas under the receiver operating characteristics curves (AUROCs) were
calculated [33]. The differences between AUROCs of the models were compared using the
method described by DeLong et al. [34].
3. Results
A total of 94 (94%) participants completed the study. Six participants were excluded
due to excessive alcohol intake, coagulation disorder and last-minute refusal to undergo
bariatric surgery. A total of 49% of the participants had histologically determined NAFLD-
fibrosis. Lifestyle characteristics of the participants with (FIB+) and without (FIB−) NAFLD-
fibrosis are shown in Table 1 and physical, biochemical, histological and genetic character-
istics in Table 2.
Table 1. Lifestyle characteristics of the participants without (FIB−) and with (FIB+) NAFLD-fibrosis, and univariable
analysis to predict NAFLD-fibrosis.
NAFLD-Fibrosis
OR (95% CI)
No (FIB−, n = 48) Yes (FIB+, n = 46)
Physical activity
Accelerometer
Use (h/day) 12.4 (11.3–13.9) 11.7 (10.6–13.4) 0.94 (0.74–1.19)
Steps (per day) 4981 (3775–6503) 4872 (4062–6628) 0.84 (1.00–1.01)
PA EE (MET-h/week) 30 (21–43) 30 (19–42) 1.00 (0.98–1.02)
MVPA (h/week) 2.1 (0.9–3.7) 2.0 (0.8–3.7) 1.00 (0.88–1.19)
Light PA (%) 32 (27–37) 31 (25–34) 0.94 (0.89–0.99) *
Sedentary (%) 65 (57–70) 68 (62–73) 1.06 (1.01–1.11) *
Sitting (h/day) 6.6 ± 0.2 6.6 ± 0.2 1.01 (0.77–1.33)
Modifiable Activity Questionnaire
PA EE (MET-h/week) 36 (17–128) 27 (9–77) 0.97 (0.93–1.00)
Occupational PA (MET-h/week) 3 (0–87) 0 (0–12) * 0.99 (0.98–1.00)
Leisure time PA (MET-h/week) 20 (12–65) 18 (9–32) 1.00 (0.98–1.03)
MVPA (h/week) 8.1 (4.4–31.4) 5.7 (2.0–16.5) * 0.97 (0.93–0.99) *
Screen time (h/day) 3 (2–4) 4 (3–6) 1.16 (0.98–1.37)
Diet
Carbohydrates E% 43 ± 1 39 ± 1 * 0.91 (0.85–0.98) *
Proteins E% 19 (18–21) 20 (19–23) 1.12 (0.99–1.27)
Fats E% 33 (28–38) 36 (33–40) * 1.09 (1.01–1.17) *
MUFA E% 10.7 ± 0.5 11.5 ± 0.4 1.10 (0.96–1.27)
PUFA E% 5.5 ± 0.2 5.6 ± 0.2 1.03 (0.79–1.34)




No (FIB−, n = 48) Yes (FIB+, n = 46)
SFA E% 10.3 ± 0.3 11.3 ± 0.4 * 1.16 (0.98–1.37)
Fiber (g/day) 21 (16–31) 19 (14–29) 0.98 (0.94–1.02)
Salt (g/day) 6.0 ± 0.3 5.7 ± 0.3 1.01 (0.85–1.19)
Coffee (cups/day) 3 (1–5) 3 (1–5) 1.00 (0.98–1.02)
Fruits & Vegetables # 4.6 ± 0.2 4.3 ± 0.2 0.93 (0.78–1.12)
Red meat # 1 (1–3) 3 (1–3) * 1.76 (1.18–2.64) **
Sleep, stress and socioeconomic
factors
Sleep length (h) 7.5 (6.7–8.0) 8.0 (6.8–8.5) 1.13 (0.80–1.60)
Sleep apnea (yes) 13 (28%) 18 (40%) 1.74 (0.73–4.18)
Fatigue & 19 (9–31) 27 (14–42) 1.01 (0.99–1.03)
Alcohol (portions/week) ## 0.6 ± 0.4 1.5 ± 0.4 ** 1.16 (0.95–1.41)
Smoking (never/current/former) 24/4/19 11/4/31 ** 3.71 (1.49–9.23) **
Duration of overweight (years) 24 (19–37) 29 (20–42) 1.03 (0.99–1.07)
Unemployed (yes) 3 (7%) 10 (23%) * 4.22 (1.08–16.53) *
Data are shown as mean ± SEM, median (25th–75th percentile) or n (%), as appropriate. Odds ratios are calculated per unit or number,
except for steps (per 100). For smoking, current and former smoker groups are combined. * p ≤ 0.05, ** p ≤ 0.01 for differences between
groups or for odds ratio. # Never = 1/few portions a month = 2/one portion a week = 3/two to four portions a week = 4/five to six
portions a week = 5/daily = 6. For fruits & vegetables, one portion comprised of e.g., fruit, small salad or side dish of vegetables. For
red meat, one portion comprised of e.g., steak, roast beef or bolognaise. & Fatigue measured by Fatigue Impact Scale (0–160). ## One
portion was defined as a bottle (33cl) of beer, a glass (12cl) of medium alcohol wine, a glass (8cl) of high alcohol wine or a glass (4cl) of
liquor. Abbreviations: E%, energy percent; EE, energy expenditure; MET, metabolic equivalent of task; MUFA, monounsaturated fatty acid;
MVPA, moderate-to-vigorous physical activity; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; PA, physical activity; PUFA,
polyunsaturated fatty acid; SFA, saturated fatty acid.
Table 2. Physical and biochemical characteristics, liver histology, and genetic characteristics of the participants without
(FIB−) and with (FIB+) NAFLD-fibrosis, and univariable analysis to predict NAFLD-fibrosis.
NAFLD-Fibrosis
OR (95% CI)
No (FIB−, n = 48) Yes (FIB+, n = 46)
Physical characteristics
Age (years) 49 (42–56) 53 (44–57) 1.03 (0.98–1.08)
Sex (female) 42 (88%) 32 (70%) * 0.29 (0.10–0.91) *
Weight (kg) 109 ± 3 116 ± 3 1.03 (0.98–1.08)
BMI (kg/m2) 39.1 ± 0.8 40.3 ± 0.7 1.04 (0.96–1.13)
Waist-to-hip ratio 0.91 ± 0.02 0.97 ± 0.02 * 1.06 (1.01–1.11) **
Systolic blood pressure
(mmHg) 124 ± 2 125 ± 1.9 1.01 (0.98–1.04)
Diastolic blood pressure
(mmHg) 79 (72–85) 77 (74–85) 1.00 (0.95–1.04)
Biochemical characteristics
fP-glucose (mol/L) 5.7 ± 0.1 5.9 ± 0.1 1.41 (0.81–2.47)
HbA1c (mmol/mol) 35 (33–37) 38 (34–45) ** 1.14 (1.04–1.24) **
fS-insulin (mU/L) 8.7 (6.2–10.8) 12.7 (7.6–17.9) *** 1.12 (1.04–1.21) **
HOMA-IR 2.2 (1.6–2.9) 4.2 (2.2–4.9) *** 1.56 (1.18–2.07) **
S-ALT (U/L) 24 (18–41) 30 (22–39) 1.01 (0.99–1.03)
S-AST (U/L) 25 (22–31) 27 (23–33) 1.03 (0.99–1.08)
AST/ALT-ratio 1.06 (0.72–1.29) 0.96 (0.81–1.13) 0.75 (0.34–1.64)
P-GGT (U/L) 21 (15–34) 28 (20–51) * 1.01 (1.00–1.03)
P-Albumin (g/L) 38.0 ± 0.3 38.9 ± 0.4 1.18 (0.99–1.40)
Platelet count (×109/L) 259 (217–288) 260 (231–288) 1.00 (0.99–1.01)




No (FIB−, n = 48) Yes (FIB+, n = 46)
fP-Triglycerides (mmol/L) 0.93 (0.80–1.20) 1.12 (0.87–1.42) * 4.62 (1.43–14.94) *
fP-HDL cholesterol (mmol/L) 1.21 (1.05–1.46) 1.13 (0.96–1.36) 0.27 (0.06–1.22)
fP-LDL cholesterol (mmol/L) 2.4 (2.1–3.1) 2.2 (1.9–2.9) 0.87 (0.57–1.31)
Lipid medication (yes) 11 (23%) 14 (30%) 1.47 (0.59–3.70)
Metabolic syndrome (yes) 23 (48%) 33 (72%) * 2.46 (1.04–5.80) *
Type 2 diabetes (yes) 12 (25%) 22 (48%) * 2.86 (1.17–7.00) *
Glucose-lowering medication
(yes) 11 (23%) 20 (43%) * 2.59 (1.06–6.30) *
Liver histology
Macrovesicular steatosis (%) 0 (0–5) 10 (0–20) ***
Ballooning (0/1/2) 48/0/0 39/4/3 **
Inflammation (0/1/2) 47/1/0 38/8/0 *
Grade of activity (0/1/2/3) 47/1/0/0 38/1/4/3 *
Stage of fibrosis (0/1/2/3/4) 48/0/0/0/0 0/39/6/1/0 ***
Genetic characteristics
PNPLA3 (CC/CG/GG) 35/12/0 25/16/3 * 2.22 (0.91–5.34)
TM6SF2 (CC/CT/TT) 40/7/0 37/7/0 0.93 (0.32–2.70)
MBOAT7 (CC/CT/TT) 21/18/7 13/19/12 2.00 (0.85–4.57)
HSD17B13 (–/-A/AA) 32/14/1 31/10/3 0.75 (0.36–2.11)
Genetic risk score
(0/1/2/3/4/5/6/7/8) 0/4/17/14/11/0/0/0/0 0/3/8/11/15/6/1/0/0 ** 1.79 (1.18–2.70) **
Data are shown as mean ± SEM, median (25th–75th percentile) or n (%), as appropriate. Odds ratios are calculated per unit or number,
except for waist-to-hip ratio (per 0.01). * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 for differences between groups or for odds ratio. Abbreviations:
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence interval; FFA, free fatty acids; fP,
fasting plasma; fS, fasting serum; GGT, γ-glutamyl-transferase; HbA1C, glycosylated hemoglobin A1C; HDL, high-density lipoprotein;
HOMA-IR, homeostasis model assessment of insulin resistance; HSD17B1, 17-β hydroxysteroid dehydrogenase; LDL, low-density
lipoprotein; MBOAT7, membrane bound O-acyltransferase domain containing 7; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio;
P, plasma; PNPLA3, patatin-like phospholipase domain-containing protein 3; TM6SF2, transmembrane 6 superfamily member 2.
3.1. Lifestyle Factors
3.1.1. Physical Activity
(i) Accelerometer recordings. The time spent in light PA was associated with a sig-
nificantly decreased risk and sedentary behavior with a significantly increased risk of
NAFLD-fibrosis (Table 1).
(ii) Modifiable Activity Questionnaire. The EE of occupational PA and time spent in
MVPA were significantly lower amongst participants in the FIB+ than in the FIB- group,
and in univariable analysis time spent in MVPA was also significantly associated with a
decreased risk of NAFLD-fibrosis (Table 1).
3.1.2. Diet
In all participants, 41 (37–46) E% of total calories was derived from carbohydrate,
19 (18–23) E% from protein and 35 (31–39) E% from fat. The energy derived from carbohy-
drates was significantly lower, while that from fats, especially from saturated fatty acids
(SFA), was significantly higher in the FIB+ compared to the FIB− group. The participants in
the FIB+ group consumed more red meat than the participants in the FIB− group (Table 1).
In univariable analysis, red meat intake and E% from fats were associated with a signifi-
cantly increased risk of NAFLD-fibrosis and E% from carbohydrates with a significantly
decreased risk of NAFLD-fibrosis (Table 1).
3.1.3. Sleep, Stress and Socioeconomic Factors
Participants in the FIB+ group consumed significantly more alcohol than participants
in the FIB- group, although alcohol consumption was within the inclusion criteria for
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NAFLD in all participants (<20 g alcohol/day for women and <30 g alcohol/day for
men) (Table 1). The proportion of participants who were current or former smokers or
unemployed was higher in the FIB+ than the FIB− group (Table 1).
3.2. Physical and Biochemical Factors, and Liver Histology
The median age of participants was 51 (44–57) years and BMI averaged 40.0 ± 0.6 kg/m2.
The participants in the FIB+ as compared to the FIB- group had significantly higher WHR,
HbA1c, insulin, HOMA-IR, GGT and triglycerides (Table 2). They also had an increased
prevalence of the metabolic syndrome (MetS), type 2 diabetes and glucose-lowering medi-
cation, and were more often men (Table 2).
All of the histologic features of NAFLD (macro-vesicular steatosis, ballooning, inflam-
mation and grade of activity) were significantly more prevalent in the FIB+ than in the
FIB− group (Table 2).
3.3. Genetic Factors
The participants in the FIB+ group were more often carriers of at least one risk variant
allele in PNPLA3 at rs738409 and had a higher GRS than those in the FIB− group (Table 2).
3.4. Multivariable Analyses
Models including lifestyle information alone (‘Lifestyle model’), physical and bio-
chemical features alone (‘Biomarker model’), GRS alone (‘Genetic model’), both physical
and biochemical parameters and GRS (‘Biomarker + Genetic model’) and all of these
(‘Comprehensive model’) were built.
We included lifestyle variables that significantly associated with fibrosis in univariable
analysis (Table 1) (light PA and sedentary behavior (accelerometer), time spent in MVPA
(MAQ), carbohydrate E%, red meat intake, smoking, unemployment) in the ‘Lifestyle
model’. The remaining independent predictors of NAFLD-fibrosis in this model were red
meat intake, carbohydrate E% and unemployment (Table 3). The AUROC of the ‘Lifestyle
model’ was 0.74 (95% CI 0.64–0.84) (Figure 2).
Table 3. Multivariable logistic regression models to predict NAFLD-fibrosis.
Model AUROC (95% CI) B S.E. OR (95% CI) p-Value
‘Lifestyle model’ 0.743 (0.643–0.843), p < 0.001
Red meat intake # 0.536 0.237 1.97 (1.18–3.28) 0.024
Carbohydrate E% −0.098 0.042 0.91 (0.84–0.99) 0.020
Unemployment (no = 0/yes = 1) 2.033 0.826 7.63 (1.51–38.52) 0.014
Constant 1.950 2.015 0.008 0.994
‘Biomarker model’ 0.776 (0.677–0.875), p < 0.001
HbA1c (mmol/mol) 0.102 0.048 1.11 (1.01–1.22) 0.032
Insulin (mU/L) 0.096 0.039 1.10 (1.02–1.19) 0.014
Triglycerides (mmol/L) 0.815 0.582 2.26 (0.72–7.07) 0.161
Constant −5.931 1.777 0.003 0.001
‘Genetic model’ 0.629 (0.513–0.745), p = 0.035
Genetic risk score 0.465 0.203 1.59 (1.07–2.40) 0.022
Constant −0.458 0.645 0.233 0.024
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Table 3. Cont.
Model AUROC (95% CI) B S.E. OR (95% CI) p-Value
‘Biomarker + Genetic model’ 0.824 (0.733–0.914), p < 0.001
HbA1c (mmol/mol) 0.126 0.051 1.13 (1.03–1.25) 0.014
Insulin (mU/L) 0.092 0.043 1.10 (1.01–1.19) 0.032
Triglycerides (mmol/L) 0.987 0.628 2.68 (0.78–9.19) 0.116
Genetic risk score 0.509 0.254 1.66 (1.01–2.74) 0.046
Constant −8.424 2.273 0.000 0.000
‘Comprehensive model’ 0.903 (0.841–0.964), p < 0.001
MVPA (h/week) −0.060 0.027 0.94 (0.89–0.99) 0.024
Red meat intake # 0.581 0.303 1.79 (0.99–3.24) 0.055
Carbohydrate E% −0.131 0.059 0.88 (0.78–0.99) 0.027
Smoking (never = 0/current or former = 1) 1.310 0.663 3.71 (1.01–13.60) 0.048
HbA1c (mmol/mol) 0.186 0.067 1.21 (1.06–1.39) 0.006
Triglycerides (mmol/L) 2.504 0.981 12.23 (1.79–83.63) 0.011
Genetic risk score 0.936 0.333 2.55 (1.33–4.90) 0.005
Constant −9.098 4.035 0.000 0.024
# Never = 1/few times in a month = 2/once a week = 3/two to four times a week = 4/five to six times a week = 5/daily = 6. Abbreviations:
AUROC, area under the receiver operating characteristic curve; B, coefficient; CI, confidence interval; E%, energy percentage; HbA1c,
glycosylated hemoglobin A1C; MAQ, Modifiable Activity Questionnaire; OR, odds ratio; MVPA, moderate-to-vigorous physical activity,
S.E., Standard Error.
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Figure 2. Receiver operating characteristic (ROC) curves of the multivariable models to predict
NAFLD-fibrosis (F ≥ 1). The areas under ROC curves (AUROC) were 0.74 for the ‘Lifestyle model’
(including red meat intake, carbohydrate E% and unemployment), 0.78 for the ‘Biomarker model’
(including HbA1c, insulin and triglycerides), 0.63 for the ‘Genetic model’ (including genetic risk
score), 0.82 for the ‘Biomarker + Genetic model’ (including HbA1c, insulin, triglycerides and genetic
risk score) and 0.90 for the ‘Comprehensive model’ (including HbA1c, triglycerides, moderate-to-
vigorous physical activity time, red meat intake, carbohydrate E%, smoking and genetic risk score).
Abbreviations: AUROC, area under receiver operating characteristic curve; CI, confidence interval.
Physical and biochemical variables that significantly associated with fibrosis in uni-
variable analysis (Table 2) were included in the ‘Biomarker model’ (sex, WHR, HbA1c,
insulin, triglycerides, MetS, type 2 diabetes). The independent remaining predictors of
NAFLD-fibrosis were HbA1c, insulin and triglycerides (Table 3). The AUROC of the
‘Biomarker model’ was 0.78 (95% CI 0.68–0.88) (Figure 2).
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For the ‘Genetic model’, GRS in addition to sex was included, and GRS predicted
fibrosis independent of sex (Table 3). The AUROC of the ‘Genetic model’ was 0.63 (95% CI
0.51–0.75) (Figure 2). Because of individual genetic variants PNPLA3 was the only one
with significant association to liver fibrosis in univariate analysis, so we also measured
performance of the model using only this variant instead of GRS. As the model with GRS
predicted liver fibrosis with higher sensitivity and specificity as measured by AUROCs
(data not shown), we included it to the multivariable models.
For the ‘Biomarker + Genetic model’, sex, WHR, HbA1c, insulin, triglycerides, MetS,
type 2 diabetes and GRS were included. The remaining predictors were HbA1c, insulin,
triglycerides and GRS. The AUROC of the ‘Biomarker + Genetic model’ was 0.82 (95% CI
0.73–0.91) (Figure 2).
Finally, all significant predictors from univariable analysis (Tables 1 and 2) were
included in the ‘Comprehensive model’. The remaining predictors were time spent in
MVPA (MAQ), red meat intake, carbohydrate E%, smoking, HbA1c, triglycerides, and
GRS (Table 3). The AUROC of the ‘Comprehensive model’ was 0.90 (95% CI 0.84–0.96)
(Figure 2).
The AUROC of the ‘Comprehensive model’ was significantly better than the AUROC
of the ‘Lifestyle model’ (p = 0.002 for comparison between models), ‘Biomarker model’
(p = 0.011), ‘Genetic model’ (p < 0.001) or ‘Biomarker + Genetic model’ (p = 0.043).
4. Discussion
Fibrosis is the best predictor of mortality in NAFLD [2,3]. Identification of patients
especially at early stages of fibrosis is important as disease regression is possible by weight
loss [35]. Since mild fibrosis can only be reliably quantified by using an invasive liver
biopsy, diagnosis of early NAFLD-fibrosis is challenging. In the present study, independent
predictors of NAFLD-fibrosis amongst obese patients referred for bariatric surgery were
low self-reported moderate-to-vigorous PA, high red meat and low carbohydrate intake,
current or former smoking, increased HbA1c and serum triglycerides and high GRS. We
found that assessment of lifestyle factors in addition to the usual physical and biochemical
predictors and GRS significantly helps in predicting NAFLD-fibrosis.
These data are the first to analyze the relationship between objectively measured
PA and biopsy-proven NAFLD-fibrosis in individuals with obesity. Light intensity PA
(1.5–3.0 METs) was inversely and sedentary behavior (<1.5 METs) positively associated
with NAFLD-fibrosis. Light intensity PA includes activities of daily living such as casual
walking or household chores, while sedentary behavior comprises activities like driving or
doing desk work at a computer. These activities are rarely reported in PA questionnaires but
can be derived from portable accelerometer data. In addition to accelerometer recordings,
the questionnaire data showed that self-reported time spent in moderate-to-vigorous PA
was inversely related to NAFLD-fibrosis and subject to large interindividual variation
(25th–75th percentile 2.7–20.8 h/week). We hypothesize based on the current study that not
only moderate-to-vigorous PA, but also light intensity PA, might be helpful in preventing
NAFLD-fibrosis in patients with obesity. It would be important to test this hypothesis in a
randomized clinical trial.
Of the dietary parameters, high relative intake of fat, especially saturated fat, in
addition to high red meat intake, low relative intake of carbohydrate and high alcohol
consumption, were significantly associated with NAFLD-fibrosis. Of these variables, red
meat intake showed the strongest association. This finding is in line with previous data
showing red meat to increase the risk of chronic liver disease [36]. The mechanisms linking
intake of red meat to advanced liver disease are uncertain but could be related to saturated
fat in red meat [37]. Regarding alcohol, the results of the present study are consistent with
recent prospective data from Finland, which showed that the risk of severe liver disease
increases slightly but steadily at all levels of alcohol consumption, even within the range
deemed acceptable for the diagnosis of NAFLD (<20 g/day for women and <30 g/day for
men) [38].
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Regarding physical and biochemical factors, the frequently assessed waist-to-hip
ratio and plasma glucose, insulin, GGT, and triglycerides were significant predictors of
NAFLD-fibrosis, in keeping with previous data [7,39]. In addition, GRS significantly
associated with NAFLD-fibrosis, consistent with data showing that GRS predicts risk
of cirrhosis in the general population [16] and NASH amongst Korean individuals with
biopsy-proven NAFLD [40]. Laboratory tests for these gene variants, other than a test
for the PNPLA3 rs738409 variant in some academic centers, are not routinely available in
clinical practice. In the current cohort, AUROC of GRS alone was poor compared to other
models implying that merely genotyping of the variants included in GRS is not sufficient
to diagnose NAFLD-fibrosis.
The participants in the current study were obese and referred for bariatric surgery. This
is an appropriate cohort if the goal is to search for predictors of liver fibrosis in the setting
of an obesity clinic, but the data do not necessarily apply to mildly overweight or normal-
weight individuals. As the study also enrolled participants in the greater area of Helsinki,
the results may not apply to individuals from other regions of the world. The present
cohort is large compared to previous studies searching for markers of histologically verified
NAFLD-fibrosis [41–43], but the results should be considered as hypothesis-generating
and need further verification. This is a challenge, however, as a liver biopsy is needed
particularly in obese subjects to accurately and successfully assess liver fibrosis.
5. Conclusions
The present data show that amongst obese individuals eligible for bariatric surgery,
those who are physically inactive, consume red meat, smoke, have elevated HbA1c and
triglycerides, and who are genetically predisposed based on GRS, are the ones suscep-
tible for NAFLD-fibrosis. Thus, the same lifestyle factors which identify those at risk
for cardiovascular disease may also increase the risk of NAFLD-fibrosis [44–46]. These
data emphasize the importance of assessing dietary and physical habits and smoking for
predicting NAFLD-fibrosis and raise the possibility that development of NAFLD-fibrosis
could be prevented by treatment of these modifiable risk factors.
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